AGM
CTMX icon

Alpine Global Management’s CytomX Therapeutics CTMX Stock Holding History

Alpine Global Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-47,723
Closed -$76K – 217
2022
Q4 		$76K Buy
47,723
+35,923
+304% +$53.1K 0.03% 365
2022
Q3 		$17K Hold
11,800
– – ﹤0.01% 169
2022
Q2 		$22K Hold
11,800
– – 0.01% 193
2022
Q1 		$32 Sell
11,800
-10,384
-47% -$39.9K 0.01% 333
2021
Q4 		$96K Buy
+22,184
New +$130K 0.01% 652
2020
Q1 		– Sell
-32,895
Closed -$273K – 272
2019
Q4 		$273K Buy
+32,895
New +$222K 0.06% 285

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alpine Global Management's CTMX Position: Q1 2023 in Review

Alpine Global Management sold out of CytomX Therapeutics (CTMX) in Q1 2023, closing a stake of 47,723 shares — an estimated $76K sold.

Alpine Global Management first reported a position in CTMX in Q4 2019 and held it in 6 quarters. The position peaked at $273K in Q4 2019. 75 funds tracked by Wall St. Rank hold CTMX as of Q1 2023.

  • Alpine Global Management reported no remaining CytomX Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 47,723 CytomX Therapeutics shares in Q1 2023, an estimated $76K.
  • Alpine Global Management first reported a position in CytomX Therapeutics in Q4 2019 and held it in 6 quarters.
  • Alpine Global Management's CytomX Therapeutics position peaked at $273K in Q4 2019.
  • 75 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.